Arlington Partners’s Acceleron Pharma XLRN Stock Holding History

Arlington Partners’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-62	Closed	-$6K	–	314
2020 Q1	$6K	Hold	62	–	–	﹤0.01%	181
2019 Q4	$3K	Buy	+62	New	+$2.83K	﹤0.01%	244
2019 Q1	–	Sell	-62	Closed	-$3K	–	251
2018 Q4	$3K	Buy	+62	New	+$3.1K	﹤0.01%	204

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Arlington Partners's XLRN Position: Q2 2020 in Review

Arlington Partners sold out of Acceleron Pharma (XLRN) in Q2 2020, closing a stake of 62 shares — an estimated $6K sold.

Arlington Partners first reported a position in XLRN in Q4 2018 and held it in 3 quarters. The position peaked at $6K in Q1 2020. 242 funds tracked by Wall St. Rank hold XLRN as of Q2 2020.

Arlington Partners reported no remaining Acceleron Pharma position as of Q2 2020 after selling out during the quarter.
Arlington Partners sold 62 Acceleron Pharma shares in Q2 2020, an estimated $6K.
Arlington Partners first reported a position in Acceleron Pharma in Q4 2018 and held it in 3 quarters.
Arlington Partners's Acceleron Pharma position peaked at $6K in Q1 2020.
242 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2020.

Based on Arlington Partners's 13F filing for Q2 2020, filed 13 Jul 2020.